These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 1538159)

  • 41. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Belshe RB; Newman FK; Frey SE
    Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
    Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
    Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
    J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
    Graham BS; Belshe RB; Clements ML; Dolin R; Corey L; Wright PF; Gorse GJ; Midthun K; Keefer MC; Roberts NJ
    J Infect Dis; 1992 Aug; 166(2):244-52. PubMed ID: 1353102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine.
    Cox JH; Garner RP; Redfield RR; Aronson NE; Davis C; Ruiz N; Birx DL
    AIDS Res Hum Retroviruses; 1999 Jun; 15(9):847-54. PubMed ID: 10381173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
    Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How antibodies block HIV infection: paths to an AIDS vaccine.
    Putney S
    Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
    Shirai A; Klinman DM
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.
    Warren RQ; Wolf H; Shuler KR; Eichberg JW; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Virol; 1990 Feb; 64(2):486-92. PubMed ID: 2404138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
    Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
    Li M; Gao F; Mascola JR; Stamatatos L; Polonis VR; Koutsoukos M; Voss G; Goepfert P; Gilbert P; Greene KM; Bilska M; Kothe DL; Salazar-Gonzalez JF; Wei X; Decker JM; Hahn BH; Montefiori DC
    J Virol; 2005 Aug; 79(16):10108-25. PubMed ID: 16051804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody-dependent enhancement and neutralization pattern of sera from SIV-infected or HIV-2-vaccinated rhesus monkeys.
    Le Grand R; Vogt G; Chapel A; Dormont D
    J Med Primatol; 1991 Jun; 20(4):172-6. PubMed ID: 1942007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.